Immunogenicity and HLA restriction of kinase mutations in colorectal adenoma and carcinoma patients

结直肠腺瘤和癌患者激酶突变的免疫原性和 HLA 限制

• 批准号: 183532
• 负责人: Holt Rob
• 金额: $ 7.29万
• 依托单位: BC Cancer, part of PHSA (Vancouver)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2009
• 资助国家: 加拿大
• 起止时间: 2009-03-01 至 2010-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=183532&lang=en
• 关键词: Cancer Vaccine; Epitope Discovery; Hla Typing; Progression Blocking Vaccine; Prophylactic Vaccine; T-Cell Epitopes

In Canada, colorectal cancer is the fourth most prevalent cancer and the second leading cause of cancer death. New approaches to colorectal cancer control are needed. Over 100 years of research have shown that the immune system can and does prevent cance

在加拿大，结直肠癌是第四大流行癌症，也是癌症死亡的第二大原因。 需要新的方法来控制结直肠癌。超过100年的研究表明，免疫系统可以而且确实可以预防癌症。